SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John R. Sashko who wrote (448)3/8/1997 10:35:00 PM
From: I. Luttichuys   of 1762
 
John, one thing I neglected to mention and feel is a pretty serious omission is that the real money here will probably be in IDEC CE9.1. This is IDEC's Rheumatoid Arthritis therapy. As you know the market is quite large. Phase III entered recently as results from Phase II were impressive. This therapy is interesting in that, as far as I know, it is the only one which actually alters the course of the disease so that perhaps ulnar deviation etc. may be avoided or at least joint damage and this may be slowed in development. This is contrast to use of NSAID and other approaches which not only do not alter the progression of the actual disease but can result in ulcers etc. as well. There was a TIME article recently (Oct. ?) in which patients in Phase II were described as having claimed that they felt they no longer had any disease at all. SmithKline is in collaboration with the development on this one and my understanding is that for every 1% market penetration IDEC can realize with this drug, 0.35 may be added to the bottom line.
Interesting, isn't it?
Please see also the recent news release on IDEC's acquisition of the small molecule agent which IDEC acquired from Pharmacia/Upjohn as a result of court order related to merger. The small molecule therapeutic interferes with topoisomerase I as I understand and is currently in Phase II. It has shown efficacy against 8 distinct CAs.
BENNETT
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News